Arcutis Shows Positive Infant Roflumilast Data Arcutis (Nasdaq: ARQT) presented infant roflumilast data reported Mar 28, 2026; full dataset and regulatory intent will determine commercial and valuation impact.

Arcutis Shows Positive Infant Roflumilast Data: Arcutis (Nasdaq: ARQT) presented infant roflumilast data reported Mar 28, 2026; full dataset and regulatory intent will determine commercial and valuation… 👈 Read full analysis #Arcutis #Roflumilast #PediatricDermatology #InfantHealth #ClinicalTrials

Arcutis Stock Awaits Next Move In A Base; Its Skin Drug Sales Grew 196% - Investor's Business Daily Arcutis Stock Awaits Next Move In A Base; Its Skin Drug Sales Grew 196%  Investor's Business Daily

Click Subscribe #Arcutis #StockMarket #Investing #Biotech #Pharmaceuticals